抗Met基因工程抗体的亲和力成熟与特性研究

发布时间：2018-03-13 16:43

本文选题：肝细胞生长因子受体　切入点：噬菌体抗体库　出处：《南京医科大学》2006年博士论文　论文类型：学位论文

【摘要】：随着恶性肿瘤对人类健康威胁的加剧，抗肿瘤研究已成为当今生命科学中极富挑战性且意义重大的领域。其中生物治疗作为手术、化疗和放疗等传统疗法外的第四种治疗手段，在肿瘤的综合治疗中发挥着愈来愈大的作用。研究发掘选择性作用于特定靶点的高效、低毒、特异性强的新型抗癌药物是当今抗肿瘤药物研究的重要方向。而以酪氨酸激酶为靶点的药物研发已成为国际抗肿瘤药物研究的热点，为此投入的研究经费也是其它任何一个非传统的肿瘤靶点药物研究所无法匹敌的。蛋白酪氨酸激酶可分为受体型和非受体型两种，它们能催化ATP上的磷酸基转移到许多重要蛋白质的酪氨酸残基上，使其发生磷酸化。蛋白酪氨酸激酶在细胞内的信号通路中占据十分重要的地位，，参与调节细胞的生长、分化、死亡等一系列生理过程。蛋白酪氨酸激酶功能的失调会引发生物体内的一系列疾病。已有的资料表明，超过50％的原癌基因和癌基因产物都具有蛋白酪氨酸激酶活性，它们的异常表达将引起细胞增殖调控发生紊乱，进而导致肿瘤发生。此外，酪氨酸激酶的异常表达还与肿瘤的侵润和转移、肿瘤新生血管的生成、肿瘤的化疗抗性密切相关。
[Abstract]:With the increasing threat of malignant tumors to human health, anti-tumor research has become a challenging and significant field in the life sciences. Among them, biotherapy is a kind of 4th kinds of treatment methods in addition to traditional treatments such as surgery, chemotherapy and radiotherapy, etc. Play a more and more important role in the comprehensive treatment of tumor. Novel anticancer drugs with strong specificity have become an important direction in the research of antitumor drugs, and the research and development of drugs targeting tyrosine kinases has become a hot spot in the international research of antitumor drugs. No other non-traditional cancer target drug institute can match the research spending. Protein tyrosine kinases can be classified into receptor type and non-receptor type. They can catalyze the phosphorylation of ATP to the tyrosine residues of many important proteins. Protein tyrosine kinase (PKK) plays an important role in the intracellular signaling pathway and participates in the regulation of cell growth and differentiation. Death and a series of physiological processes. Disorders of the function of protein tyrosine kinase can cause a series of diseases in organism. Available data show that more than 50% proto-oncogene and oncogene products have the activity of protein tyrosine kinase. In addition, the abnormal expression of tyrosine kinase is closely related to tumor invasion and metastasis, tumor neovascularization and tumor chemotherapeutic resistance.
【学位授予单位】：南京医科大学
【学位级别】：博士
【学位授予年份】：2006
【分类号】：R392

【共引文献】